FDA lays down the law on gene therapy, offering guidances on both diseases and procedures
As first announced in January, the FDA’s Center for Biologics Evaluation and Research (CBER) on Wednesday offered a swath of new draft guidance documents on …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
